SCHEMBL279886

SCHEMBL279886

Cc1ccc(C(=O)CN2CCC(N)C2)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 2/20 0.40
HRH2 P25021 1/20 0.40
HRH1 P35367 1/20 0.40
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
DAO P14920 1/20 0.39
HTR1A P08908 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
POLB P06746 3/20 0.36
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280340 0.80 NPC1 (0.40) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279992 0.79 DAO (0.44) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279616 0.77 RAB9A (0.49) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279955 0.76 HPGD (0.56) ALDH1A1HPGDRAB9ANPC1DAO
SCHEMBL279637 0.76 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279970 0.74 DAO (0.43) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279862 0.74 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL279666 0.74 POLB (0.36) ALDH1A1KMT2AMEN1HRH2HRH1
SCHEMBL279617 0.73 DAO (0.42) ALDH1A1KMT2AMEN1HPGDRAB9A
SCHEMBL22946992 0.73 KMT2A (0.47) ALDH1A1KMT2AMEN1HRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ALDH1A1 2047/4885KMT2A 3398/4885MEN1 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.